Head-to-head · free

Ascentage Pharma Group International vs Xenon Pharmaceuticals Inc.

AAPG vs XENE — return on capital, cash generation, margins and balance sheet side by side.

AAPG

2 / 3

measures where AAPG leads

XENE

1 / 3

measures where XENE leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureAAPGXENE · FY2025
Revenue——
Net income—(345.9M)
Revenue growth (yearly, multi-year)——
Free cash flow—(279.9M)
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity-156.5%-51.8%
Gross margin91.5%—
Operating margin-208.6%-4974.3%
Net debt / EBITDA0.46x0.54x

Figures are as reported by each company; latest fiscal year shown.

Where Ascentage Pharma Group International's cash went

Not reported yet.

Full AAPG profile →

Where Xenon Pharmaceuticals Inc.'s cash went (FY2025)

Capital spending
$799000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full XENE profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons